South Rampart Pharma

South Rampart Pharma’s proprietary compounds effectively reduce pain and fever in preclinical studies without liver and kidney toxicity associated with current treatment. The company’s non-opioid compounds, licensed from LSU Health New Orleans, also greatly reduce the potential for abuse. The company won a $1.9 million National Institutes of Health Phase I/II award in 2022 to support the clinical development of its lead, non-opioid candidate, SRP-3D (DA).